2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Title: HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥20
Lead Author: Jong Chul Park
Abstract: TPS6109
Poster presentation: Monday, June 2, 2025
